Chemoimmunotherapy for canine lymphosarcoma.
Thirty-two dogs with naturally occurring multicentric lymphosarcoma were randomly assigned to one of two treatment groups. One half of the animals received combination chemotherapy plus vitamin injections (controls) while the other half received indentical chemotherapy plus injections of chemically-modified tumor cell extract in Freund's complete adjuvant (vaccinates). Clinical staging revealed no bias between groups but showed that prognosis could be closely correlated with the severity of disease at initial presentation. Twenty dogs (62%), including 11 vaccinates and 9 controls, responded favorably to chemotherapy and were evaluated for length of first remission and total survival time. Both parameters were significantly longer in vaccinated dogs than in controls. These data suggest that immunological stimulation may be a helpful adjunct to conventional therapy in selected types of cancer when immunological principles are observed.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D005620:Freund's Adjuvant / Q000627:therapeutic use; D007167:Immunotherapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy / Q000662:veterinary*; D008297:Male; D011379:Prognosis
D000970:Antineoplastic Agents; D005620:Freund's Adjuvant